RegenxBio, Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company which is cementing its place as a global leader in gene therapies, targeting the treatment of retinal, metabolic, and neurodegenerative diseases. The Company is leveraging a proprietary NAV Technology Platform to develop a pipeline of candidates...
Biotech Companies continue to show resurgence with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector, there are some companies that...
Clovis Oncology Inc (NASDAQ: CLVS) is a commercial stage biotechnology company engaged in developing and commercializing oncology treatments worldwide. The Company develops diagnostic tools through its partners, which can identify patients who will benefit the most from its developmental programs, focused on targeting specific subsets of cancer. The Company’s...
Alopecia Areata is an autoimmune/polygenic skin disease that causes loss of hair on the scalp and face and is estimated to affect over 6.8 million people in the U.S alone. There is currently no cure available for this disorder, with dermatologists using Corticosteroids, minoxidil 5%,...
DermTech Inc (NASDAQ: DMTK) is pioneering a new way for detecting skin cancer through a smart sticker, which eliminates the need for a biopsy and the use of a scalpel to collect skin samples for detection of melanoma. The technology promises to revolutionize the melanoma...
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a clinical-stage pharmaceutical company targeting ophthalmic conditions with large unmet medical needs, recently announced that the pivotal Phase 2b/3 Saturn-1 trial which is evaluating TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis has met all pre-specified primary and...
Anavex Life Sciences Corp (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company that is developing a pipeline of therapeutic candidates that target the Central Nervous System (CNS) by leveraging its expertise in precision genetic medicine. The Company has announced that its predictive biomarker of response established...
Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biotechnology company, developing leading-edge orally delivered large molecule therapeutics, announced pivotal 6-month bone mineral density (BMD) results from the Phase 2 clinical trial of EB613, intended for the treatment of osteoporosis. EB613, the Company’s lead candidate for the...
Alzheimer’s is the sixth leading cause of death in the U.S, a disease that causes irreversible degeneration of the brain cells and affects a person’s cognitive and behavioral abilities such as impaired judgment, deteriorating memory and personality changes with the gradual loss of motor abilities...
ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company that focuses on creating innovative therapeutics for treatment of autoimmune, inflammatory and oncology disorders with primary focus on orphan and rare diseases. The Company’s approach is centered on developing discrete chemokine or chemoattractant receptors that block...
